The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain and/or a non- viable attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain for use the treatment and/or prevention of cancer recurrence/progression. Preferably the cancer is bladder cancer.